MOUNTAIN VIEW, Calif. — November 19, 2025 — Leads & Copy —
RenovoRx, Inc. (Nasdaq: RNXT) announced that CEO Shaun Bagai will participate in the Alliance Global Partners (AGP) Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20, 2025. The event will be hosted by Scott Henry, Managing Director and Healthcare Analyst, at AGP.
Bagai will provide updates on RenovoRx’s commercial efforts and market traction, highlighting the increasing clinical demand and adoption of RenovoCath as a standalone, targeted drug-delivery device across both new and repeat customers. The company recently reported its third-quarter financial results for 2025, with year-to-date revenue reaching approximately $900,000.
Bagai will also discuss advancements in RenovoRx’s clinical research and scientific programs, including the Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine delivered via RenovoCath (IAG) in locally advanced pancreatic cancer (LAPC). Updates on the company’s post-marketing registry study, which captures real-world data on the safety and effectiveness of RenovoCath in patients with solid tumors will also be provided.
The company also noted ongoing support of investigator-initiated trials in borderline resectable and oligometastatic pancreatic cancer. These cost-neutral studies are designed to broaden the application for the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform.
AGP Emerging AgBiotech/Bio-Solutions Virtual Showcase Details:
Date: Thursday, November 20, 2025
Time: 2:00 PM ET
Speaker: Shaun Bagai, CEO
Moderator: Scott Henry, AGP Managing Director and Healthcare Analyst
Webcast: https://ir.renovorx.com/news-events/ir-calendar-events
To schedule a one-on-one investor meeting with Mr. Bagai, please contact your A.G.P. representative or KCSA Strategic Communications at RenovoRx@KCSA.com.
RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company focused on developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared local drug-delivery device, targeting high unmet medical needs.
The company’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while minimizing a therapy’s toxicities versus systemic intravenous therapy.
In addition to the RenovoCath device, RenovoRx is evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon new drug application approval by the FDA. RenovoRx is also commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices.
Several customers have already initiated repeat orders as RenovoRx expands the number of medical institutions initiating new RenovoCath orders, including several high-volume National Cancer Institute-designated centers. To meet the anticipated demand, RenovoRx will explore further revenue-generating activity.
Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@KCSA.com
Source: RenovoRx, Inc.
